Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Satralizumab in Muscular Dystrophy, Duchenne: NCT06450639 Clinical Landscape Report 2026
18 September 2026
NCT06450639 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tranexamic Acid in Anemia: NCT06519422 Clinical Landscape Report 2026
18 September 2026
NCT06519422 clinical landscape for Anemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Osivelotor in Anemia, Sickle Cell: NCT06507904 Clinical Landscape Report 2026
18 September 2026
NCT06507904 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxycarbamide in Stroke: NCT06526117 Clinical Landscape Report 2026
18 September 2026
NCT06526117 clinical landscape for Stroke: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zinc Sulfate Hydrate in Anemia, Sickle Cell: NCT06561061 Clinical Landscape Report 2026
18 September 2026
NCT06561061 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ITU512 in Anemia, Sickle Cell: NCT06546670 Clinical Landscape Report 2026
18 September 2026
NCT06546670 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxycarbamide in Hematologic Diseases: CTRI/2024/08/072780 Clinical Landscape Report 2026
18 September 2026
CTRI/2024/08/072780 clinical landscape for Hematologic Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Forazapadin in Muscular Dystrophy, Duchenne: NCT06565208 Clinical Landscape Report 2026
18 September 2026
NCT06565208 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CS-101 in Acute Chest Syndrome: NCT06565026 Clinical Landscape Report 2026
18 September 2026
NCT06565026 clinical landscape for Acute Chest Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxycarbamide in Anemia, Sickle Cell: NCT06578507 Clinical Landscape Report 2026
18 September 2026
NCT06578507 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ketorolac Tromethamine in Vaso-occlusive crisis: NCT06579703 Clinical Landscape Report 2026
18 September 2026
NCT06579703 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gefurulimab in Myasthenia Gravis: NCT06607627 Clinical Landscape Report 2026
18 September 2026
NCT06607627 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.